JPS5859914A - 吸入用薬物 - Google Patents

吸入用薬物

Info

Publication number
JPS5859914A
JPS5859914A JP57127788A JP12778882A JPS5859914A JP S5859914 A JPS5859914 A JP S5859914A JP 57127788 A JP57127788 A JP 57127788A JP 12778882 A JP12778882 A JP 12778882A JP S5859914 A JPS5859914 A JP S5859914A
Authority
JP
Japan
Prior art keywords
drug
particles
diameter
capsules
sodium cromoglycate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57127788A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0468285B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
レイモンド・ブライアン・フオレスタ−
テレンス・デイビツド・ボ−アドマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fisons Ltd
Original Assignee
Fisons Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10523464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS5859914(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fisons Ltd filed Critical Fisons Ltd
Publication of JPS5859914A publication Critical patent/JPS5859914A/ja
Publication of JPH0468285B2 publication Critical patent/JPH0468285B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP57127788A 1981-07-24 1982-07-23 吸入用薬物 Granted JPS5859914A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8122846 1981-07-24
GB8122846 1981-07-24

Publications (2)

Publication Number Publication Date
JPS5859914A true JPS5859914A (ja) 1983-04-09
JPH0468285B2 JPH0468285B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-11-02

Family

ID=10523464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57127788A Granted JPS5859914A (ja) 1981-07-24 1982-07-23 吸入用薬物

Country Status (26)

Country Link
US (1) US4590206A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0072046B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS5859914A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR890002908B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU540826B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE893912A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1187415A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH657273A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3268533D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK159716C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI822548A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2510405B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR76229B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK10088A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU196904B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE53640B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL66375A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU84291A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA19548A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY8700857A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO156394C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ201341A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH22759A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT75310B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG68487G (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA825222B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001508793A (ja) * 1997-01-20 2001-07-03 アストラ・アクチエボラーグ ０．２８から０．３８ｇ／ｍｌの流動かさ密度を有する吸入用新規製剤、その製剤を調製する方法およびその使用
JP2001508792A (ja) * 1997-01-20 2001-07-03 アストラ・アクチエボラーグ フォルモテロールを含む０．２８から０．３８ｇ／ｍｌの流動かさ密度を有する吸入用新規製剤
JP2001509811A (ja) * 1997-01-20 2001-07-24 アストラ・アクチエボラーグ ブデソニドを含む０．２８から０．３８ｇ／ＭＬの流動かさ密度を有する吸入用新規製剤
JP2001517691A (ja) * 1997-09-29 2001-10-09 インヘール セラピューティック システムズ， インコーポレイテッド 多孔性微粒子および使用方法

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
EP0309519B1 (en) * 1987-04-09 1992-07-08 FISONS plc Pharmaceutical compositions containing pentamidine
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5198221A (en) * 1989-05-17 1993-03-30 Fisons Plc Pharmaceutical composition
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
EP0465841A3 (en) * 1990-06-13 1992-10-14 Hoechst Aktiengesellschaft Quick acting pharmaceutical inhalation forms of diuretics
US5228607A (en) * 1991-06-07 1993-07-20 Tvp, Inc. Rack mountable on a trailer hitch ball
DE69332240T2 (de) * 1992-06-12 2003-04-10 Teijin Ltd., Osaka Ultrafeines pulver zur inhalation und dessen herstellung
US6509006B1 (en) * 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
NZ257212A (en) 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US7448375B2 (en) * 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
IS1736B (is) * 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
HU222355B1 (hu) * 1993-10-01 2003-06-28 Astra Aktiebolag Eljárás és berendezés finom gyógyszerhatóanyag-porok kezelésére és feldolgozására
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
PT748213E (pt) 1994-03-07 2004-08-31 Nektar Therapeutics Metodos e composicoes para administracao pulmonar de insulina
JPH10500672A (ja) * 1994-05-18 1998-01-20 インヘイル セラピューティック システムズ，インコーポレイティド インターフェロンの乾燥粉末製剤に関する方法及び組成物
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
SE9700136D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
CA2218879A1 (en) * 1995-05-12 1996-11-14 Genentech, Inc. Coarse spray delivery of functional biologic materials
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
WO1998029098A1 (en) * 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
WO1999036095A1 (en) * 1998-01-13 1999-07-22 Astrazeneca Uk Limited PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D2) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING β2-ADRENORECEPTOR AGONIST ACTIVITY
JP3828363B2 (ja) * 1998-04-20 2006-10-04 株式会社コスモ総合研究所 ポリエステル及びその製造法
US6451349B1 (en) 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
EP1210067A2 (en) * 1999-08-25 2002-06-05 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
JP2003525081A (ja) 2000-02-28 2003-08-26 ヴェクチュラ リミテッド 経口薬物の送達における改良、またはそれに関する改良
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
WO2002009669A2 (en) * 2000-08-01 2002-02-07 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution and particles made thereby
SE516555C2 (sv) * 2000-08-04 2002-01-29 Microdrug Ag Elektropulver
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US20030125236A1 (en) * 2000-12-29 2003-07-03 Advenced Inhalation Research, Inc. Particles for inhalation having rapid release properties
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
AU2002230993B2 (en) * 2000-12-29 2006-02-02 Alkermes, Inc. Particles for inhalation having sustained release properties
DE10128779A1 (de) † 2001-06-13 2003-01-02 Boehringer Ingelheim Pharma Verfahren zur Reinigung von Hartgelatinekapseln
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
WO2003020197A1 (en) 2001-09-05 2003-03-13 Vectura Limited Improvements in or relating to the delivery of oral drugs
US8524279B2 (en) 2001-11-01 2013-09-03 Novartis Ag Spray drying methods and related compositions
EP1455755B1 (en) 2001-11-20 2013-04-17 Civitas Therapeutics, Inc. Improved particulate compositions for pulmonary delivery
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
DK1458360T3 (da) 2001-12-19 2011-08-29 Novartis Ag Pulmonær afgivelse af aminoglycosider
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
EP1490031A1 (en) * 2002-03-07 2004-12-29 Vectura Limited Fast melt multiparticulate formulations for oral delivery
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CA2483914A1 (en) * 2002-05-07 2003-11-20 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
EP1578536B1 (en) 2002-12-30 2017-02-08 Novartis AG Prefilming atomizer
WO2005025506A2 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
US20080213593A1 (en) * 2005-01-21 2008-09-04 President And Fellows Of Harvard College Systems And Methods For Forming Fluidic Droplets Encapsulated In Particles Such As Colloidal Particles
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
ES2691033T3 (es) * 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
KR101699574B1 (ko) 2009-12-09 2017-01-24 아사히 가라스 가부시키가이샤 Ｅｕｖ 리소그래피용 반사층이 형성된 기판, ｅｕｖ 리소그래피용 반사형 마스크 블랭크, ｅｕｖ 리소그래피용 반사형 마스크, 및 그 반사층이 형성된 기판의 제조 방법
CA2767773C (en) 2011-02-11 2015-11-24 Grain Processing Corporation Composition comprising a salt and a crystallization interrupter
CA2869849A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5294413A (en) * 1976-01-23 1977-08-09 Fisons Ltd Soft pellet or granular medicine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957965A (en) * 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
GB1569611A (en) * 1976-01-23 1980-06-18 Fisons Ltd Pelletised or granular medicament formulation
GB1520248A (en) * 1975-07-24 1978-08-02 Fisons Ltd Sodium cromoglycate containing medicament
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB1549229A (en) * 1976-09-23 1979-08-01 Fisons Ltd High density sodium cromoglycate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5294413A (en) * 1976-01-23 1977-08-09 Fisons Ltd Soft pellet or granular medicine

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001508793A (ja) * 1997-01-20 2001-07-03 アストラ・アクチエボラーグ ０．２８から０．３８ｇ／ｍｌの流動かさ密度を有する吸入用新規製剤、その製剤を調製する方法およびその使用
JP2001508792A (ja) * 1997-01-20 2001-07-03 アストラ・アクチエボラーグ フォルモテロールを含む０．２８から０．３８ｇ／ｍｌの流動かさ密度を有する吸入用新規製剤
JP2001509811A (ja) * 1997-01-20 2001-07-24 アストラ・アクチエボラーグ ブデソニドを含む０．２８から０．３８ｇ／ＭＬの流動かさ密度を有する吸入用新規製剤
JP2010059181A (ja) * 1997-01-20 2010-03-18 Astrazeneca Ab ０．２８から０．３８ｇ／ｍｌのかさ密度を有する吸入用新規製剤、その製剤を調製する方法およびその使用
JP2010059180A (ja) * 1997-01-20 2010-03-18 Astrazeneca Ab フォルモテロールを含む０．２８から０．３８ｇ／ｍｌのかさ密度を有する吸入用新規製剤
JP2010059179A (ja) * 1997-01-20 2010-03-18 Astrazeneca Ab ブデソニドを含む０．２８から０．３８ｇ／ＭＬのかさ密度を有する吸入用新規製剤
JP2001517691A (ja) * 1997-09-29 2001-10-09 インヘール セラピューティック システムズ， インコーポレイテッド 多孔性微粒子および使用方法
JP2001517692A (ja) * 1997-09-29 2001-10-09 インヘール セラピューティック システムズ， インコーポレイテッド ネブライザにおける使用のための安定化調製物
JP2003525842A (ja) * 1997-09-29 2003-09-02 インヘール セラピューティック システムズ， インコーポレイテッド 計量吸入器における使用のための安定化調製物
JP2010047615A (ja) * 1997-09-29 2010-03-04 Nektar Therapeutics 計量吸入器における使用のための安定化調製物
JP2013199497A (ja) * 1997-09-29 2013-10-03 Nektar Therapeutics 多孔性微粒子および使用方法

Also Published As

Publication number Publication date
IE53640B1 (en) 1989-01-04
KR840000226A (ko) 1984-02-18
NO156394B (no) 1987-06-09
DK159716B (da) 1990-11-26
FR2510405A1 (fr) 1983-02-04
NO156394C (no) 1987-09-16
EP0072046A1 (en) 1983-02-16
AU540826B2 (en) 1984-12-06
IE821770L (en) 1983-01-24
LU84291A1 (fr) 1983-02-07
SG68487G (en) 1988-02-19
BE893912A (fr) 1983-01-24
IL66375A0 (en) 1982-11-30
HK10088A (en) 1988-02-12
MA19548A1 (fr) 1983-04-01
PT75310B (en) 1985-11-29
AU8635582A (en) 1983-02-10
FI822548L (fi) 1983-01-25
ZA825222B (en) 1983-05-25
FI822548A0 (fi) 1982-07-20
DE3268533D1 (en) 1986-02-27
CH657273A5 (fr) 1986-08-29
NZ201341A (en) 1985-05-31
PH22759A (en) 1988-12-12
DK159716C (da) 1991-04-29
PT75310A (en) 1982-08-01
NO822556L (no) 1983-01-25
MY8700857A (en) 1987-12-31
FI822548A7 (fi) 1983-01-25
KR890002908B1 (ko) 1989-08-11
EP0072046B1 (en) 1986-01-15
DK325982A (da) 1983-01-25
GR76229B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1984-08-04
JPH0468285B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-11-02
CA1187415A (en) 1985-05-21
HU196904B (en) 1989-02-28
FR2510405B1 (fr) 1985-07-26
US4590206A (en) 1986-05-20

Similar Documents

Publication Publication Date Title
JPS5859914A (ja) 吸入用薬物
US5260306A (en) Inhalation pharmaceuticals
GB2105189A (en) Inhalation drugs
FI65547C (fi) Foerfarande foer framstaellning av foer inhalering avsedda mjuka dinatriumkromoglykatpelletar
US4147766A (en) Macrospherical particles of anti-perspirants
US6221398B1 (en) Process for the preparation of respirable particles
US4161516A (en) Composition for treating airway disease
US3634582A (en) Pharmaceutical compositions
US4009280A (en) Powder composition for inhalation therapy
EP1232745A1 (en) Carrier particles for use in dry powder inhalers
GB1569611A (en) Pelletised or granular medicament formulation
CN101312713A (zh) 可吸入的药物
AU2003226842B2 (en) A method for treating carrier particles and its use
CA1116516A (en) Medicament composition in soft pellet or granule form
WO2002100378A2 (en) Process for the preparation of a particulate material
CA1144862A (en) Composition
JPH0142950B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE45261B1 (en) Disodium cromoglycate pellets or granules
HK1084897B (en) Improvements in and relating to carrier particles for use in dry powder inhalers